来氟米特在PTEN缺陷前列腺癌中触发合成致死
该研究探索来氟米特抑制从头嘧啶合成对PTEN缺陷前列腺癌细胞的影响,采用体外生长实验和体内异种移植模型,发现来氟米特可抑制肿瘤生长,可能与DNA损伤过度累积有关,提示PTEN缺失与来氟米特联合存在合成致死治疗机会。
要点
- PTEN缺陷前列腺癌细胞对来氟米特抑制从头嘧啶合成敏感。
- 来氟米特在体外和体内均观察到肿瘤生长抑制。
- 该效应可能与DNA损伤过度累积有关。
核心结论
- PTEN缺失与来氟米特处理在前列腺癌中产生合成致死,可能为该患者群体提供治疗机会。
研究设计与样本
- 研究采用体外生长实验和体内异种移植模型测试抑制从头嘧啶合成对前列腺细胞系的影响。
主要发现
- PTEN缺陷前列腺癌细胞系对来氟米特抑制从头嘧啶合成敏感。
- 来氟米特处理后在体外和体内均观察到肿瘤生长抑制。
- 肿瘤生长抑制可能由于DNA损伤的过度累积。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The loss of PTEN function presents in up to 50% of late-stage prostate cancers, and is therefore a potential target for therapeutics. PTEN-deficient cells depend on de novo pyrimidine synthesis, a feature that can present a vulnerability. METHODS: We utilized in vitro growth assays and in vivo xenograft models to test the effect of de novo pyrimidine synthesis inhibition on prostate cell lines. RESULTS: Here, we demonstrate that PTEN-deficient prostate cancer cell lines are susceptible to inhibition of de novo pyrimidine synthesis by leflunomide. Tumor growth inhibition was observed in vitro and in vivo following leflunomide treatment, and is likely due to an overwhelming accumulation of DNA damage. CONCLUSIONS: Our work highlights that synthetic lethality arises upon the combination of PTEN loss and leflunomide treatment in prostate cancer, and may present a therapeutic opportunity for this patient population.
引用
- Ozturk S, Mathur D, Zhou RW, et al. Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32661432. doi:10.1038/s41391-020-0251-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。